Sarnova

Sarnova

Sarnova operates from dual bases in Stockholm and Dublin, reflecting a common Scandinavian-Irish corridor for family capital seeking to access the European Union's life sciences ecosystem. Public filings indicate the office was formed to steward private wealth into healthcare, though the originating family and founding year remain undisclosed. The Dublin office likely serves as a gateway to Ireland's medtech cluster, which hosts 18 of the world's top 25 medical-technology companies and is the largest employer of medtech personnel in Europe per capita. The office concentrates on direct equity investments in European life sciences companies, spanning medical devices, diagnostics, and digital health. Sarnova participates in early-stage and growth rounds, occasionally co-investing alongside specialized healthcare venture funds. The firm has backed companies developing non-invasive monitoring technologies and point-of-care diagnostic platforms, though specific portfolio names are not publicly catalogued. The geographic focus remains primarily on Northern Europe — Sweden, Ireland, Denmark, and the United Kingdom — where the office can leverage local networks and regulatory expertise. Sarnova maintains a deliberately light public footprint, with no known website or LinkedIn presence as of mid-2026. The absence of disclosed assets under management, team size, or named principals suggests a tightly held structure, possibly still managed by the founding principals or a small cadre of investment professionals. No affiliated philanthropic foundations or adjacent investment vehicles have been identified through public record. The office's operational opacity aligns with a broader cohort of European single-family offices that prioritize privacy over institutional visibility, often investing through nominee entities or co-investment vehicles to limit public attribution. In October 2024, regulatory filings in Ireland confirmed the firm's continued active status and registration in Dublin (per Irish Companies Registration Office, 2024). The structural differentiator for Sarnova lies in its jurisdiction pairing: Stockholm supplies proximity to Scandinavia's deep life-science research base — Karolinska Institutet, SciLifeLab, and a dense cluster of university spinouts — while Dublin grants uninterrupted access to the EU regulatory framework and Ireland's favorable holding-company regime. This dual-axis model permits the office to source pre-commercial innovation in the Nordics and structure investments through Irish vehicles optimized for cross-border exits, a configuration rarely replicated at this scale of discreet family capital.